Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: The flint men's health study

Prostate

Volumn 68, Issue 3, 2008, Pages 296-305

  Sarma, Aruna V ^a,b,e   Dunn, Rodney L ^a   Lange, Leslie A ^c   Ray, Anna ^a   Wang, Yunfei ^c   Lange, Ethan M ^c,d   Cooney, Kathleen A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d IL   (United States)

^e NONE   (United States)

Author keywords

African American; Prostate cancer; Single nucleotide polymorphism

Indexed keywords

ANDROSTANOLONE; AROMATASE; CYTOCHROME P450 17; CYTOCHROME P450 3A4; SOMATOMEDIN C; STEROID 5ALPHA REDUCTASE 2; TESTOSTERONE;

ADULT; AFRICAN AMERICAN; AGED; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CANCER CONTROL; CANCER DIAGNOSIS; CANCER RISK; CELL PROLIFERATION; CONTROLLED STUDY; DEGRADATION; DISEASE COURSE; DISEASE FREE SURVIVAL; EPITHELIUM CELL; GENETIC POLYMORPHISM; HEALTH STATUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

AFRICAN AMERICANS; AGED; CASE-CONTROL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DNA, NEOPLASM; HAPLOTYPES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; ISOENZYMES; MALE; MICHIGAN; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 39449089183     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20696     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward H, Murray T, Xu J, Thun MJ. Cancer Statistics, 2007. CA: Cancer J Clin 2007;57 43-66.
2. Bostwick DC, Burke HB, Djakiew D, Euling S, Ho S, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, Timms B. Human prostate cancer risk factors. Cancer 2004;101:2371-2400.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer Statistics, 2006. CA: Cancer J Clin 2006;56 106-130
4. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med 1993;118:793-803.
5. Whittemore AS, Wu AH, Kolonel LN, John EM, Gallagher RP, Howe GR, West DW, Teh CZ, Stamey T. Family history and prostate cancer risk in Black, White, and Asian men in the United States and Canada. Am J Epidemiol 1995;141:732-740.
6. Singh A, Chau CH, Price DK, Figg WD. Mechanisms of disease: Polymorphisms of androgen regulatory genes in the development of prostate cancer. Nat Clin Pract 2005;2:101-107.
7. Nam RK, Zhang WW, Trachtenberg J, Jewett MAS, Emami M, Vesprini D, Chu W, Ho M, Sweet J, Evans A, Toi A, Pollack M, Narod SA. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003;12:1429-1437.
8. Jones J, Clemmons D. Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 1995;16:3-34.
9. Chan JM, Stampfer MJ, Giovannucci E, Ma J, Pollak M. Insulin-like growth factor 1 (ICF-1), IGF-binding protein-3 and prostate cancer risk: Epidemiological studies. Growth Hormone & IGF Research 2000;10(Suppl-1):S32- S33.
10. Wilbert D, Griffin J, Wilson J. Characterization of the cytosol androgen receptor of the human prostate. J Clin Endocrinol Metab 1983;56:113-120.
11. Reichardt J, Makridakis N, Henderson B, Yu M, Pike M, Ross R. Genetic variability of the human SRD5A2 gene: Implications for prostate cancer risk. Cancer Res 1995;55:3973-3975.
12. Bjelfman C, Soderstrom TG, Brekkan E, Norlen BJ, Egevad L, Unge T, Andersson S, Rane A. Differential gene expression of steroid 5 alpha-reductase-2 in core needle biopsies from malignant and benign prostatic tissue. J Clin Endocrinol Metab 1997;82:2210-2214.
13. Makridakis N, Ross R, Pike M, Chang L, Stanczyk FZ, Kolonel LN, Shi CY, Yu M, Henderson B, Reichardt J. A prevalent missense substitution that modulates activity of prostatic steroid 5 alpha-reductase. Cancer Res 1997;57:1020-1022.
14. Nam RK, Toi A, Vesprini D, Ho M, Chu W, Harvie S, Sweet J, Trachtenberg J, Jewett MAS, Narod SA. The V89L polymorphism of the SRD5A2 gene predicts prostate cancer presence and progression. Urology 2000;57:199-204.
15. Lewis DFV, Lee-Robichaud P. Molecular modelling of steroidogenic cytochromes P450 from families CYP11, CYP17, CYP19 and CYP21 based on the CYP102 crystal structure. J Steroid Biochem Mol Biol 1998;66:217-233.
16. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3 A4. J Natl Cancer Inst 1998;90:1225-1229.
17. Gsur A, Bernhofer G, Hinteregger S, Haidinger G, Schatzi G, Madersbacher S, Marberger M, Vutuc C, Micksche M. A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int J Cancer 2000;87:434-437.
18. Haiman CA, Stampfer MJ, Giovannucci E, Ma J, Decalo NE, Kantoff PW, Hunter DJ. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol Biomarkers Prev 2001;10:743-748.
19. Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S, Williamson R. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene C YP17. Hum Mol Genet 1994;3:1873-1876.
20. Paris PL, Kupelian PA, Hall JM, Williams TL, Levin H, Klein EA, Casey G, Witte JS. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev 1999;8:901-905.
21. Ntais C, Polycarpou A, Tsatsoulis A. Molecular epidemiology of prostate cancer: Androgens and polymorphisms in androgen-related genes. Eur J Endocrinol 2003;149:469-477.
22. Latil A, Azzouzi R, Cancel G, Guillaume E, Cochan-Priollet B, Berthon P, Cussenot O. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 2001;92:1130-1137.
23. Modugno F, Weissfeld JL, Trump DL, Zmuda JM, Shea P, Cauley JA, Ferrell RF. Allelic variants of aromatase and the androgen and estrogen receptors: Toward a multigenic model of prostate cancer risk. Clin Cancer Res 2001;7:3092-3096.
24. Jernstom H, Deal C, Wilkin F, Chu W, Tao Y, Majeed N, Hudson T, Narod SA, Pollak M. Genetic and non-genetic factors associated with variation of plasma levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 2001;10:377-384.
25. Heeringa SG, Alcser KH, Doerr K, Strawderman M, Cooney K, Medbery B, Schottenfeld D. Potential selection bias in a community-based study of PSA levels in African-American men. J Clin Epidemiol 2001;54:142-148.
26. Cooney KA, Strawderman MS, Wojno KJ, Doerr KM, Taylor A, Alcser KH, Heeringa SG, Taylor JM, Wei JT, Montie JE, Schottenfeld D. Age-specific distribution of serum prostate-specific antigen in a community-based study of African-American men [Review] [20 refs]. Urology 2001;57:91-96.
27. Coughlin SS, Hall IJ. A review of genetic polymorphisms and prostate cancer risk. Ann Epidemiol 2002;12:182-196.
28. Canzian F, McKay J, Cleveland R, Dossus L, Biessy C, Rinaldi S, Landi S, Boillot C, Monnier S, Chajes V, Clavel-Chapelon F, Tehard B, Change-Claude J, Linseisen J, Lahmann P, Pischon T, Trichopoulos D, Trichopoulou A, Zilis D, Palli D, Tumino R, Vineis P, Berrino F, Bueno-de-Mesquita H, van Gils C, Peeters P, Pera G, Ardanaz E, Chirlaque M-D, Quiros J, Larranaga N, Martinez-Garcia C, Allen N, Key T, Bingham S, Khaw K-T, Slimani N, Norat T, Riboli E, Kantoff PW. Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: Results from the EPIC study. Br J Cancer 2006;94:299-307.
29. Lewontin RC. The interaction of selection and linkage. I. General considerations; heterotic models. Genetics 1964;49:49-67.
30. Devlin B, Risch N. A comparison of linkage disequilibrium measures for fine-scale mapping. Genomics 1995;29:311-322.
31. Pritchard JK, Stephens M, Rosenberg NA, Donnelly P. Association mapping in structured populations. Am J Human Genet 2000;67:170-181.
32. Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, Sigurdsson A, Benediktsdottir KR, Cazier JB, Sainz J, Jakobsdottir M, Kostic J, Magnusdottir DN, Ghosh S, Agnarsson K, Birgisdottir B, Le Roux L, Olafsdottir A, Blondal T, Andresdottir M, Gretarsdottir OS, Bergthorsson JT, Gudbjartsson D, Gylfason A, Thorleifsson G, Manolescu A, Kristjansson K, Geirsson G, Isaksson H, Douglas J, Johansson JE, Bälter K, Wiklund F, Montie JE, Yu X, Suarez BK, Ober C, Cooney KA, Gronberg H, Catalona WJ, Einarsson GV, Barkardottir RB, Gulcher JR, Kong A, Thorsteinsdottir U & Stefansson K. A common variant associated with prostate cancer in European and African Populations. Nat Genet 2006;38:652-658.
33. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Human Genet 2002;70:425-434.
34. Gsur A, Feik E, Madersbacher S. Genetic polymorphisms and prostate cancer risk. World J Urol 2004;21:414-423.
35. Ntais C, Polycarpou A, Ioannidis JPA. Association of the CYP17 gene polymorphism with the risk of prostate cancer: A meta-analysis. Cancer Epidemiol Biomarkers Prey 2003;12:120-126.
36. Plummer SJ, Conti DV, Paris PL, Curran AP, Casey G, Witte JS. CYP3A4 and CYP3A5 genotypes,, haplotypes, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003;12:928-932.
37. Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE, Reichardt JK. Association of missense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 1999;354:975-978.
38. Davis DL, Russell DW. Unusual length polymorphism in human steroid 5{alpha}-reductase type 2 gene (SRD5A2). Hum Mol Genet 1993;2:820.
39. Hsing AW, Chen C, Chokkalingam AP, Gao YT, Dightman DA, Nguyen HT, Deng J, Cheng J, Sesterhenn IA, Mostofi FK, Stanczyk FZ, Reichardt JKV. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: A population-based case-control study. Cancer Epidemiol Biomarkers Prev 2001;10:1077-1082.
40. Wu AH, Whittemore AS, Kolonel LN, John EM, Gallagher RP, West DW, Hankin J, Teh CZ, Dreon DM, Paffenbarger RS Jr. Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev 1995;4:735-741.
41. Ntais C, Polycarpou A, Ioannidis JPA. SRD5A2 gene polymorphisms, the risk of prostate cancer: A meta-analysis. Cancer Epidemiol Biomarkers Prev 2003;12:618-624.
42. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-i, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54:5474-5478.
43. Cheng I, Stram DO, Penney KL, Pike M, Le Marchand L, Kolonel LN, Hirschhorn J, Altshuler D, Henderson BE, Freedman ML. Common genetic variation in IGF1 and prostate cancer risk in the multiethnic cohort. J Natl Cancer Inst 2006;98:123-134.
44. Platz EA, Pollak MN, Rimm EB, Majeed N, Tao Y, Willett WC, Giovannucci E. Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. Cancer Epidemiol Biomarkers Prev 1999;8:1107-1110.